Giant cell tumor of the fifth lumbar vertebra with a three-year follow-up: case report and review of the literature

We report the case of a patient with giant cell tumor of the L5 vertebra. A 35-year-old female patient with giant cell tumor of the L5 vertebra was subjected to a combined treatment. Three years after treatment, there is no recurrence of the disease and no increase in the residual tumor’s size. Giant cell tumor of the L5 vertebra requires careful planning of treatment and close follow-up of the patient

Acute Infrarenal Aortic Thrombosis Presenting With Flaccid Paraplegia

Study Design. This study is a case report. Objective. To report a case of a patient with paraplegia and low back pain, who was diagnosed with acute infrarenal aortic thrombosis. Summary of Background Data. There have been few reports in the literature regarding acute aortic thrombosis presenting with paraplegia. Methods. A 56-year-old man was referred to our emergency department with flaccid paraplegia and low back pain. Clinical examination and imaging revealed acute infrarenal aortic thrombosis, with lower limb ischemia. The patient underwent transcutaneous embolectomy. Results. Despite successful revascularization, the patient finally died because of development of revascularization syndrome. Conclusion. Acute aortic occlusion is a catastrophic event and may present with paraplegia, because of acute spinal cord ischemia. This can mislead the clinician to a wrong diagnosis and delay initiation of definite treatment

Teriparatide Treatment in Patients with Pregnancy- and Lactation-Associated Osteoporosis

Pregnancy- and lactation-associated osteoporosis (PLO) is a rare disease, presenting in most cases with severe back pain due to low energy vertebral fractures (VFs). Our purpose was to assess the effect of teriparatide (TPTD) vs. conventional management on areal bone mineral density (aBMD) and trabecular bone score (TBS) in patients with PLO. A multicenter retrospective cohort study concerning premenopausal women with PLO. Nineteen women were treated with TPTD (20 mu g/day) (group A) plus calcium and vitamin D and eight women with calcium and vitamin D only (group B) for up to 24 months. The primary end-point was between group differences in lumbar spine (LS) and total hip (TH) aBMD, and TBS at 12 and 24 months. Patients in group A had sustained a median of 4.0 VFs (3-9) vs. 2.5 VFs (1-10) in group B (p = 0.02). At 12 months, patients on TPTD vs. controls achieved a mean aBMD increase of 20.9 +/- 11.9% vs. 6.2 +/- 4.8% at the LS (p < 0.001), 10.0 +/- 11.6% vs. 5.8 +/- 2.8% at the TH (p = 0.43), and 6.7 +/- 6.9% vs. 0.9 +/- 3.7% in TBS (p = 0.09), respectively. At 24 months, seven patients on TPTD and six controls achieved a mean LS aBMD increase of 32.9 +/- 13.4% vs. 12.2 +/- 4.2% (p = 0.001). P1NP levels during the first month of TPTD treatment were positively correlated with the 1-year LS aBMD change (r = 0.68, p = 0.03). No new clinical fractures occurred while on-treatment. In patients with PLO, TPTD treatment resulted in significantly greater increases in LS aBMD compared with calcium and vitamin D supplementation at 12 and 24 months

Hip and Knee Section, Treatment, Debridement and Retention of Implant: Proceedings of International Consensus on Orthopedic Infections

acute periprosthetic joint infectio